New Zealand markets open in 1 hour 59 minutes

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.3950+0.1200 (+3.66%)
As of 02:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.2750
Open3.2900
Bid3.4000 x 1300
Ask3.4200 x 800
Day's range3.3700 - 3.4900
52-week range1.3000 - 4.3800
Volume398,342
Avg. volume1,520,436
Market cap41.719M
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)-3.2600
Earnings date07 Mar 2024 - 11 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.60
  • GlobeNewswire

    Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

    FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar, will present an overview of the company at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentation ar

  • GlobeNewswire

    Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

    Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health’s National Cancer Institute (NCI)FLORHAM PARK, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the first patient has been enrolled in its Phase 1b clinical trial evaluating iopofosine I 131, a novel phospholi

  • GlobeNewswire

    Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

    FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Tranche A warrants issued as part of the private placement announced in September 2023 have been exercised in full. All participants in the previous financing, led by Rosalind Advisors, exercised their warrants with gross proceeds